BR112018008136A2 - peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo - Google Patents

peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo

Info

Publication number
BR112018008136A2
BR112018008136A2 BR112018008136A BR112018008136A BR112018008136A2 BR 112018008136 A2 BR112018008136 A2 BR 112018008136A2 BR 112018008136 A BR112018008136 A BR 112018008136A BR 112018008136 A BR112018008136 A BR 112018008136A BR 112018008136 A2 BR112018008136 A2 BR 112018008136A2
Authority
BR
Brazil
Prior art keywords
amino acid
peptide
absent
side chain
disorder
Prior art date
Application number
BR112018008136A
Other languages
English (en)
Inventor
Morgan Richard
Original Assignee
Hox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hox Therapeutics Ltd filed Critical Hox Therapeutics Ltd
Publication of BR112018008136A2 publication Critical patent/BR112018008136A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a novos peptídeos, os quais prejudicam a regulação dependente de pbx da transcrição gênica e que, assim, têm utilidade no tratamento ou na prevenção de transtornos nos quais ocorre divisão celular anormal. especificamente, a invenção provê um peptídeo que compreende a sequência de aminoácidos (i): y1x1x2kwx3x4x5x6x7y2 (i), em que a sequência de x1 a x7 é uma sequência de aminoácidos incluindo pelo menos 7 aminoácidos, a qual pode opcionalmente ser interrompida por um ou dois resíduos de aminoácidos entre uma ou mais das 9 posições dos aminoácidos aqui definidos; x1 é selecionado a partir de w, t, pe, kqi, w, pqt, h, r1 e ausente; x2 é um aminoácido com uma cadeia lateral aromática ou cisteína; x3 é um aminoácido hidrofóbico; x4 é um aminoácido com uma cadeia lateral carregada; x5 é um aminoácido com uma cadeia lateral; x6 é um aminoácido ou está ausente; x7 é um ou mais aminoácidos ou está ausente; e y1 e y2, cada qual, estão ausentes ou são um peptídeo compreendendo um polímero catiônico de aminoácidos básicos, desde que pelo menos um entre y1 e y2 esteja presente.
BR112018008136A 2015-10-21 2016-10-20 peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo BR112018008136A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1518700.8A GB2543550A (en) 2015-10-21 2015-10-21 Peptides
PCT/GB2016/053282 WO2017068353A1 (en) 2015-10-21 2016-10-20 Peptides

Publications (1)

Publication Number Publication Date
BR112018008136A2 true BR112018008136A2 (pt) 2018-11-06

Family

ID=55131441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008136A BR112018008136A2 (pt) 2015-10-21 2016-10-20 peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo

Country Status (13)

Country Link
US (1) US10494412B2 (pt)
EP (2) EP3610883A1 (pt)
JP (1) JP2018533570A (pt)
KR (1) KR20180080217A (pt)
CN (1) CN108430491A (pt)
AU (1) AU2016341494A1 (pt)
BR (1) BR112018008136A2 (pt)
CA (1) CA3002739A1 (pt)
EA (1) EA201890900A1 (pt)
ES (1) ES2775740T3 (pt)
GB (1) GB2543550A (pt)
MX (1) MX2018004930A (pt)
WO (1) WO2017068353A1 (pt)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE69536065D1 (de) * 1994-01-14 2010-05-27 Rath Matthias Hydrophile Signal-Oligopeptide und Verfahren der therapeutischen Anwendung
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1399483B1 (en) 2001-01-05 2010-04-14 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
GB0229151D0 (en) * 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20050148627A1 (en) 2003-03-31 2005-07-07 Jeffery Carter Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
US7259266B2 (en) 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
EP1909811B1 (en) * 2005-06-29 2012-02-01 St. George's Enterprises Limited Hox peptides as pbx modulators for the treatment of cancer
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
CN102089320B (zh) * 2008-01-24 2015-11-25 埃斯佩兰斯医药公司 溶解结构域融合构建体及其制备和使用方法
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
GB2543550A (en) 2017-04-26
ES2775740T3 (es) 2020-07-28
EP3610883A1 (en) 2020-02-19
MX2018004930A (es) 2018-11-09
US20180282384A1 (en) 2018-10-04
AU2016341494A1 (en) 2018-05-24
JP2018533570A (ja) 2018-11-15
EA201890900A1 (ru) 2018-10-31
EP3364992A1 (en) 2018-08-29
CA3002739A1 (en) 2017-04-27
EP3364992B1 (en) 2019-12-04
ES2775740T8 (es) 2020-08-06
CN108430491A (zh) 2018-08-21
US10494412B2 (en) 2019-12-03
KR20180080217A (ko) 2018-07-11
GB201518700D0 (en) 2015-12-02
WO2017068353A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112015018255A2 (pt) Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatia
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
MD3347002T2 (ro) Tratamentul bolii Alzheimer într-o populație specifică de pacienți
BR112017010832A2 (pt) composições de aminoácido para o tratamento de sintomas de doença
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112015028414A2 (pt) composição farmacêutica de micela de polímero
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
DOP2018000218A (es) Inhibidor de esterasa c1 conjugado y sus usos
EA202092748A1 (ru) Модуляторы экспрессии apol1
BR112017008805A2 (pt) tratamento de córnea usando laminina
BR112017019431A2 (pt) material de implante de compósito
BR112017015307A2 (pt) modulação de expressão de apolipoproteína c-iii (apociii) em populações de lipodistrofia
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
BR112018008136A2 (pt) peptídeo, composição farmacêutica, uso de um peptídeo, método para a prevenção ou tratamento de uma condição ou transtorno e método de manutenção ou expansão de células-tronco ex vivo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements